8-K filing — Silo Pharma, Inc. (SILO)
Filed: 2026-10-02 AccNo: 0001213900-26-106435 Size: 353 KB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Silo Pharma Enters Asset Purchase Agreement With Norsight Consulting; To Buy Software And Intellectual Property From Norsight Consulting
On October 1, 2026, Silo Pharma, Inc. (the "Company") entered into an asset purchase agreement (the "Agreement") with Norsight Consulting Inc., an Arkansas corporation (the "Seller"). Pursuant to
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Silo Pharma's QwikAgents Subsidiary Expands AI Agent Platform With New Client, To Support Client-Provided Nvidia API Keys, Adds Hermes Agent Runtime
Silo Pharma Receives U.S. Patent Office Notice Of Allowance For Application Covering SPC-15, Its Novel Intranasal Therapeutic Targeting Post-Traumatic Stress Disorder
The invention, titled "Compositions and Methods for the Prevention of Stress-Induced Fear, Depressive-Like and Anxiety-Like Behavior," is also covered by a corresponding patent issued by the Japan Patent Office